Chemotherapy-induced peripheral neurotoxicity in immune-deficient mice: New useful ready-to-use animal models

[1]  M. Berciano,et al.  Reactive nucleolar and Cajal body responses to proteasome inhibition in sensory ganglion neurons. , 2014, Biochimica et biophysica acta.

[2]  David L. Bennett,et al.  Evaluation of tubulin polymerization and chronic inhibition of proteasome as citotoxicity mechanisms in bortezomib-induced peripheral neuropathy , 2014, Cell cycle.

[3]  Maree T. Smith,et al.  Pathobiology of cancer chemotherapy-induced peripheral neuropathy (CIPN) , 2013, Front. Pharmacol..

[4]  M. Pisanu,et al.  Monitoring response to cytostatic cisplatin in a HER2(+) ovary cancer model by MRI and in vitro and in vivo MR spectroscopy , 2013, British Journal of Cancer.

[5]  Y. H. Han,et al.  Dexamethasone inhibits the effect of paclitaxel on human ovarian carcinoma xenografts in nude mice. , 2013, European review for medical and pharmacological sciences.

[6]  G. Cavaletti,et al.  Bortezomib-Induced Painful Peripheral Neuropathy: An Electrophysiological, Behavioral, Morphological and Mechanistic Study in the Mouse , 2013, PloS one.

[7]  C. Segebarth,et al.  Synergistic effect of cisplatin and synchrotron irradiation on F98 gliomas growing in nude mice , 2013, Journal of synchrotron radiation.

[8]  M. Goetz,et al.  Matrix detachment and proteasomal inhibitors diminish Sulf-2 expression in breast cancer cell lines and mouse xenografts , 2013, Clinical & Experimental Metastasis.

[9]  Lin Mei,et al.  Paclitaxel drug delivery systems , 2013, Expert opinion on drug delivery.

[10]  S. Warmann,et al.  Effect of sorafenib combined with cytostatic agents on hepatoblastoma cell lines and xenografts , 2012, British Journal of Cancer.

[11]  B. Giometto,et al.  Treatment for paraneoplastic neuropathies. , 2012, The Cochrane database of systematic reviews.

[12]  Jianmin Yang,et al.  Bortezomib suppresses the growth of leukemia cells with Notch1 overexpression in vivo and in vitro , 2012, Cancer Chemotherapy and Pharmacology.

[13]  Guido Cavaletti,et al.  Chemotherapy-induced peripheral neurotoxicity (CIPN): an update. , 2012, Critical reviews in oncology/hematology.

[14]  G. Cavaletti,et al.  Comparison of neuropathy-inducing effects of eribulin mesylate, paclitaxel, and ixabepilone in mice. , 2011, Cancer research.

[15]  G. Cavaletti,et al.  Multimodal assessment of painful peripheral neuropathy induced by chronic oxaliplatin-based chemotherapy in mice , 2011, Molecular pain.

[16]  G. Cavaletti,et al.  Neurophysiological and neuropathological characterization of new murine models of chemotherapy-induced chronic peripheral neuropathies , 2010, Experimental Neurology.

[17]  G. Cavaletti,et al.  The role of oxidative stress and anti-oxidant treatment in platinum-induced peripheral neurotoxicity. , 2010, Current cancer drug targets.

[18]  G. Cavaletti,et al.  Glutamate Carboxypeptidase Inhibition Reduces the Severity of Chemotherapy-Induced Peripheral Neurotoxicity in Rat , 2010, Neurotoxicity Research.

[19]  G. Cavaletti,et al.  Bortezomib‐induced painful neuropathy in rats: A behavioral, neurophysiological and pathological study in rats , 2010, European journal of pain.

[20]  B. Aggarwal,et al.  Curcumin circumvents chemoresistance in vitro and potentiates the effect of thalidomide and bortezomib against human multiple myeloma in nude mice model , 2009, Molecular Cancer Therapeutics.

[21]  M. Fujita,et al.  Mechanical allodynia induced by paclitaxel, oxaliplatin and vincristine: different effectiveness of gabapentin and different expression of voltage-dependent calcium channel alpha(2)delta-1 subunit. , 2009, Biological & pharmaceutical bulletin.

[22]  M. Friedlander,et al.  Mechanisms underlying chemotherapy-induced neurotoxicity and the potential for neuroprotective strategies. , 2008, Current medicinal chemistry.

[23]  P. Dougherty,et al.  Behavioral and electrophysiological studies in rats with cisplatin-induced chemoneuropathy , 2008, Brain Research.

[24]  A. Argyriou,et al.  Bortezomib-induced peripheral neuropathy in multiple myeloma: a comprehensive review of the literature. , 2008, Blood.

[25]  P. Dougherty,et al.  Quantitative sensory findings in patients with bortezomib-induced pain. , 2007, The journal of pain : official journal of the American Pain Society.

[26]  P. Ghezzi,et al.  Cisplatin-induced peripheral neuropathy: neuroprotection by erythropoietin without affecting tumour growth. , 2007, European journal of cancer.

[27]  Misaki Matsumoto,et al.  Inhibition of Paclitaxel-Induced A-Fiber Hypersensitization by Gabapentin , 2006, Journal of Pharmacology and Experimental Therapeutics.

[28]  N. Munshi,et al.  Emerging trends in the clinical use of bortezomib in multiple myeloma. , 2005, Clinical lymphoma & myeloma.

[29]  G. Nicolini,et al.  Morphological and morphometric analysis of paclitaxel and docetaxel-induced peripheral neuropathy in rats. , 2005, European journal of cancer.

[30]  A. Fagan,et al.  A proteasomal stress response: pre‐treatment with proteasome inhibitors increases proteasome activity and reduces neuronal vulnerability to oxidative injury , 2004, Journal of neurochemistry.

[31]  T. Hickish,et al.  Oxaliplatin, fluorouracil, and leucovorin as adjuvant treatment for colon cancer. , 2004, The New England journal of medicine.

[32]  T. Libermann,et al.  Molecular sequelae of proteasome inhibition in human multiple myeloma cells , 2002, Proceedings of the National Academy of Sciences of the United States of America.

[33]  Huifang Huang,et al.  Solution Structure of a Cisplatin-Induced DNA Interstrand Cross-Link , 1995, Science.

[34]  G. Cavaletti,et al.  Experimental Peripheral Neuropathy Induced in Adult Rats by Repeated Intraperitoneal Administration of Taxol , 1995, Experimental Neurology.

[35]  Roy E. Furman,et al.  Cisplatin neuropathy. Risk factors, prognosis, and protection by WR‐2721 , 1988, Cancer.

[36]  A. Kato,et al.  Effects of the prostaglandin E1 analog limaprost on mechanical allodynia caused by chemotherapeutic agents in mice. , 2009, Journal of pharmacological sciences.

[37]  I. Barajon,et al.  Morphometric study of the sensory neuron and peripheral nerve changes induced by chronic cisplatin (DDP) administration in rats , 2004, Acta Neuropathologica.

[38]  G. Cavaletti,et al.  Experimental cisplatin neuronopathy in rats and the effect of retinoic acid administration , 2004, Journal of Neuro-Oncology.

[39]  G. Cavaletti,et al.  Effect on the peripheral nervous system of the short-term intravenous administration of paclitaxel in the rat. , 1997, Neurotoxicology.

[40]  S. Horwitz,et al.  Mechanism of action of taxol. , 1992, Trends in pharmacological sciences.